Laduviglusib (GMP)

Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor. In Vitro: Laduviglusib (GMP) (20 μM, 21 days) transdifferentiates mouse fibroblasts to neurons (determined by increased number of TAUEGFP-/TUJ1-positive neuronal cells)^[1].
Laduviglusib (GMP) (3-5 μM, 2 days) induces somatic cells differentiation of pluripotent stem (PS) cells (the detailed method refers to the reference)^[2].
Laduviglusib (GMP) (12 μM, 5 days) converts human fibroblasts (HFF) into functional cardiomyocytes^[3].
Laduviglusib (GMP) (3 μM, 4 days, hESCs) activates the canonical WNT signaling pathway, confirmed by β-catenin translocation into the nucleus^[4].
Laduviglusib (GMP) (in MEFs expressing MyoD) enhances the marked increase in the number of proliferative cells led by RepSox (GMP) (HY-13012G) together with Forskolin (HY-15371)^[5].
Laduviglusib (GMP) (5 μM, 1 day) can be used to generate islets (hCiPSC-islets) from human chemically induced pluripotent stem cells (hCiPSC)^[6].